HCW Biologics Issues Shares Through Warrant Exercise

HCW Biologics ( (HCWB) ) has provided an announcement.

On May 13, 2025, HCW Biologics Inc. entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd., granting pre-funded warrants for up to 513,140 shares of common stock. Following this, on May 15 and May 22, 2025, Armistice exercised some of these warrants, resulting in the issuance of 177,140 and 126,000 shares respectively, with 210,000 warrants remaining.

The most recent analyst rating on (HCWB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.

Spark’s Take on HCWB Stock

According to Spark, TipRanks’ AI Analyst, HCWB is a Underperform.

HCW Biologics is facing substantial financial challenges, with declining revenues and high leverage being the most significant issues. The technical analysis suggests bearish trends, and the valuation is unattractive due to negative earnings. These factors result in a low overall stock score.

To see Spark’s full report on HCWB stock, click here.

More about HCW Biologics

HCW Biologics Inc. operates in the biotechnology industry, focusing on developing innovative therapies.

Average Trading Volume: 654,788

Technical Sentiment Signal: Sell

Current Market Cap: $17.54M

See more data about HCWB stock on TipRanks’ Stock Analysis page.